Rizatriptan-D6 benzoate salt is intended for use as an internal standard for the quantification of rizatriptan by GC- or LC-MS. Rizatriptan benzoate salt (T1512) is an agonist of the serotonin receptor subtypes 5-HT1B and 5-HT1D. It is selective for 5-HT1B and 5-HT1D receptors over 5-HT1A receptors. Rizatriptan induces vasoconstriction in isolated human middle meningeal arteries. In vivo,rizatriptan reduces head grooming,the number of oculotemporal strokes,eye blinking,and one-eye closures in a Cacna1a mutant transgenic mouse model of migraine. Formulations containing rizatriptan have been used in the treatment of migraine.